Ian D Pavord Selected Research

mepolizumab

11/2022	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation.
4/2022	Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.
1/2022	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
1/2022	From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
10/2021	The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
1/2021	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.
1/2021	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.
11/2020	Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.
7/2020	Response to mepolizumab treatment is sustained across 4-weekly dosing periods.
1/2020	Usability of mepolizumab single-use prefilled autoinjector for patient self-administration.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ian D Pavord Research Topics

Disease

134	Asthma (Bronchial Asthma) 11/2022 - 04/2002
48	Inflammation (Inflammations) 11/2022 - 12/2002
36	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 10/2003
15	Cough 01/2022 - 01/2003
10	Chronic Cough 01/2022 - 01/2004
9	Eosinophilia 03/2022 - 01/2005
7	COVID-19 10/2022 - 01/2020
7	Bronchitis 08/2006 - 05/2002
5	Infections 01/2022 - 08/2020
4	Pneumonia (Pneumonitis) 08/2020 - 06/2015
4	Respiratory Hypersensitivity 11/2013 - 12/2002
3	Rhinosinusitis 01/2022 - 01/2020
2	Airway Remodeling 10/2022 - 01/2019
2	Hypersensitivity (Allergy) 01/2022 - 05/2019
2	Cystic Fibrosis (Mucoviscidosis) 09/2021 - 03/2016
2	Lung Diseases (Lung Disease) 01/2021 - 09/2010
2	Atopic Dermatitis (Atopic Eczema) 01/2020 - 05/2018
2	Obstructive Lung Diseases (Obstructive Lung Disease) 11/2019 - 01/2016
2	Cough-Variant Asthma 01/2004 - 01/2004
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022
1	Churg-Strauss Syndrome (Allergic Angiitis) 01/2022
1	Symptom Flare Up 01/2022
1	Obesity 01/2022
1	Pulmonary Embolism 01/2021
1	Disease Susceptibility (Diathesis) 10/2020
1	Bacterial Infections (Bacterial Infection) 08/2020

Drug/Important Bio-Agent (IBA)

70	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 01/2003
46	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2005
24	mepolizumabIBA 11/2022 - 03/2009
24	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022 - 01/2005
15	dupilumabIBA 01/2022 - 01/2018
14	Biological ProductsIBA 01/2022 - 09/2011
14	Monoclonal AntibodiesIBA 01/2022 - 08/2012
14	Bronchodilator Agents (Bronchodilators)IBA 01/2022 - 02/2006
12	Interleukin-13IBA 01/2022 - 11/2004
11	CytokinesIBA 10/2022 - 12/2002
10	Interleukin-5 (Interleukin 5)IBA 10/2022 - 10/2013
9	Immunoglobulin E (IgE)IBA 01/2022 - 12/2010
8	Pharmaceutical PreparationsIBA 01/2022 - 03/2004
8	GlucocorticoidsIBA 10/2021 - 09/2014
7	Interleukin-4 (Interleukin 4)IBA 10/2022 - 12/2002
7	SteroidsIBA 01/2022 - 08/2012
7	InterleukinsIBA 01/2022 - 08/2012
6	Formoterol Fumarate (Oxis)FDA Link 01/2021 - 05/2009
6	Capsaicin (Zostrix)FDA Link 01/2016 - 02/2005
5	Budesonide (Pulmicort)FDA LinkGeneric 01/2021 - 05/2009
5	Fluticasone (Cutivate)FDA LinkGeneric 01/2019 - 04/2006
4	Azithromycin (Zithromax)FDA LinkGeneric 11/2022 - 07/2019
4	benralizumabIBA 01/2022 - 08/2015
4	Salmeterol Xinafoate (Serevent)FDA Link 02/2016 - 04/2006
4	Methacholine Chloride (Methacholine)FDA Link 11/2013 - 04/2002
3	fluticasone furoate FDA Link 01/2022 - 06/2015
3	C-Reactive ProteinIBA 10/2021 - 01/2014
3	Anti-Bacterial Agents (Antibiotics)IBA 09/2021 - 11/2015
3	fevipiprantIBA 01/2021 - 01/2016
3	Prednisolone (Predate)FDA LinkGeneric 11/2020 - 09/2014
3	GoldIBA 07/2019 - 01/2018
2	Prostaglandin D2IBA 10/2022 - 01/2004
2	Purinergic P2X3 ReceptorsIBA 01/2022 - 10/2020
2	Omalizumab (Xolair)FDA Link 01/2022 - 01/2016
2	GefapixantIBA 01/2022 - 10/2020
2	reslizumabIBA 01/2022 - 08/2015
2	anti-IgE antibodiesIBA 01/2022 - 01/2011
2	Antiviral Agents (Antivirals)IBA 10/2021 - 08/2020
2	prostaglandin D2 receptorIBA 01/2021 - 01/2016
2	Albuterol (Salbutamol)FDA LinkGeneric 01/2021 - 01/2019
2	Prednisone (Sone)FDA LinkGeneric 01/2020 - 11/2013
2	LipidsIBA 01/2019 - 01/2018
2	ChemokinesIBA 01/2018 - 08/2006
2	vilanterolIBA 01/2016 - 06/2015
2	Beclomethasone (Beclometasone)FDA Link 02/2011 - 08/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2007 - 02/2006
2	Etanercept (Enbrel)FDA Link 01/2007 - 02/2006
2	Chemokine ReceptorsIBA 09/2005 - 12/2002
1	Nicotine FDA Link 10/2022
1	Leukotriene E4IBA 10/2022
1	Reducing AgentsIBA 01/2022
1	AntibodiesIBA 01/2022
1	Interleukin-5 Receptors (Interleukin 5 Receptor)IBA 01/2022
1	LigandsIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	neuromedin UIBA 01/2022
1	Interleukin-33IBA 10/2021
1	itepekimabIBA 10/2021
1	Interleukin-6 (Interleukin 6)IBA 07/2021
1	Interleukin-8 (Interleukin 8)IBA 07/2021
1	ProstaglandinsIBA 01/2021
1	EnzymesIBA 10/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020
1	Angiotensin Receptor AntagonistsIBA 10/2020

Therapy/Procedure

49	Therapeutics 11/2022 - 01/2003
11	Biological Therapy 11/2022 - 01/2016
8	Bronchial Thermoplasty 01/2016 - 03/2007
5	Drug Therapy (Chemotherapy) 10/2021 - 01/2018
4	Precision Medicine 01/2021 - 02/2016
2	Length of Stay 07/2021 - 01/2016
2	Nebulizers and Vaporizers (Inhaler) 01/2021 - 01/2020
2	Drug Tapering 12/2014 - 08/2008
1	Patient Readmission 10/2020
1	Artificial Respiration (Mechanical Ventilation) 08/2020